[144] Cadrenal Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 reporting a proposed sale of 881 common shares through Merrill Lynch (address listed) with an approximate aggregate market value of $12,343.19 and an approximate sale date of 10/01/2025 on NASDAQ. The filing states these shares were acquired as Founders Shares on 01/25/2022 from the issuer and payment was recorded on the acquisition date. The notice also lists prior open-market sales by Quang X. Pham during the past three months totaling 14,819 shares on multiple dates between 08/27/2025 and 09/29/2025 with aggregate gross proceeds reported in the filing. The filer represents no undisclosed material adverse information and includes the standard Rule 144/10b5-1 attestations.

Positive

• Clear compliance disclosure of proposed sale details including broker, share count, value, and sale date
• Acquisition origin stated as Founders Shares acquired from the issuer on 01/25/2022
• Recent sales fully reported for transparency (dates and gross proceeds provided)

Negative

• Multiple recent sales by the same person in the past three months (14,819 shares), which could indicate ongoing insider liquidity

Insights

Securities Analyst

TL;DR: Routine insider sale notice; modest share amount relative to outstanding shares, with recent prior sales documented.

The Form 144 documents a proposed sale of 881 common shares valued at $12,343.19 scheduled for 10/01/2025 and confirms these are founders shares acquired 01/25/2022. The filing also records multiple open-market dispositions by Quang X. Pham totaling 14,819 shares across late August and September 2025. Compared with the reported 2,046,854 shares outstanding, the aggregated recent activity is small in percentage terms. This filing is procedural and provides transparency on planned insider liquidity while including the standard attestation regarding material nonpublic information.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure showing adherence to Rule 144 requirements and 10b5-1 attestations.

The document appears to meet Rule 144 disclosure requirements by identifying the class of security, broker, acquisition history, and recent sales by the relevant person. It specifies the nature of acquisition as founders shares from the issuer and lists broker details for the planned sale. The signature attestation about lack of undisclosed material information aligns with customary governance practices. No extraordinary governance issues or departures are stated in the filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 824 A1A North Suite 200 Ponte Vedra Beach FL 32082	881	12343.19	2046854	10/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/25/2022	Founders Shares	Issuer			881	01/25/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	08/27/2025	3836	53455.56
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	08/28/2025	1193	16540.64
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	09/24/2025	2581	36108
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	09/25/2025	6790	95661.94
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	09/29/2025	419	5869.5

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Cadrenal Therapeutics (CVKD) report in this Form 144?

The filing reports a proposed sale of 881 common shares through Merrill Lynch valued at $12,343.19 with an approximate sale date of 10/01/2025 on NASDAQ.

Who acquired the shares being sold and when were they acquired?

The shares were acquired as Founders Shares from the issuer on 01/25/2022 and the filing lists 881 shares to be sold.

Has the filer sold other shares recently?

Yes. The filing lists sales by Quang X. Pham totaling 14,819 shares across 08/27/2025 to 09/29/2025 with gross proceeds shown for each trade.

Which broker is handling the proposed sale?

The proposed sale is listed with Merrill Lynch (address provided in the filing).

Does the filer assert there is undisclosed material information?

The person for whose account the securities are to be sold represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.